Thomas A. Vassiliades, Jr, Peter C. Block, Lawrence H. Cohn, David H. Adams, Jeffrey S. Borer, Ted Feldman, David R. Holmes, Warren K. Laskey, Bruce W. Lytle, Michael J. Mack and David O. Williams
This joint position statement represents the combined efforts of four professional societies (Society of Thoracic Surgeons [STS], American Association for Thoracic Surgery [AATS], American College of Cardiology [ACC], and Society for Cardiovascular Angiography and Interventions [SCAI]), two government agencies (the U.S. Food and Drug Administration [FDA] and the Centers for Medicare and Medicaid Services [CMS]), and numerous industry representatives to assess the foreseeable directions of a class of emerging technologies being developed to enable the percutaneous treatment of cardiac valve dysfunction.
- Ahmed El-Eshmawi, MD, Javier G. Castillo, MD, David H. Adams, MD
- Joanna Chikwe, MD, Eugene H. Blackstone, MD, David H. Adams, MD
Bioprosthetic aortic valve replacement: revisiting prosthesis choice in patients younger than 50 years oldSamuel R. Schnittman, MD, David H. Adams, MD, Shinobu Itagaki, MD, Nana Toyoda, MD, Natalia N. Egorova, PhD, Joanna Chikwe, MD
- Samuel R. Schnittman, MD, David H. Adams, MD, Shinobu Itagaki, MD, Nana Toyoda, MD, Natalia N. Egorova, PhD, Joanna Chikwe, MD